Cubist Systematic Strategies LLC boosted its holdings in C.R. Bard, Inc. (NYSE:BCR) by 294.2% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,587 shares of the medical instruments supplier’s stock after acquiring an additional 2,677 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in C.R. Bard were worth $1,150,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Leucadia National Corp bought a new position in C.R. Bard in the 2nd quarter worth about $13,184,000. Vivaldi Asset Management LLC bought a new position in C.R. Bard in the 2nd quarter worth about $57,965,000. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in C.R. Bard by 12.3% in the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 16,951 shares of the medical instruments supplier’s stock worth $5,358,000 after acquiring an additional 1,859 shares during the last quarter. Artemis Investment Management LLP increased its stake in C.R. Bard by 33.4% in the 2nd quarter. Artemis Investment Management LLP now owns 41,313 shares of the medical instruments supplier’s stock worth $13,068,000 after acquiring an additional 10,354 shares during the last quarter. Finally, Sirios Capital Management L P bought a new position in C.R. Bard in the 2nd quarter worth about $71,393,000. Institutional investors and hedge funds own 79.11% of the company’s stock.

BCR has been the topic of a number of research analyst reports. ValuEngine lowered C.R. Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Barclays upped their target price on C.R. Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research note on Monday, November 6th. Jefferies Group restated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research note on Thursday, September 14th. Cowen restated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research note on Friday, November 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $303.50.

In related news, VP Frank Lupisella, Jr. sold 9,173 shares of the stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $325.00, for a total transaction of $2,981,225.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Timothy P. Collins sold 8,388 shares of the stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $322.00, for a total value of $2,700,936.00. The disclosure for this sale can be found here. Insiders sold a total of 210,032 shares of company stock valued at $68,777,261 over the last quarter. Company insiders own 0.80% of the company’s stock.

C.R. Bard, Inc. (BCR) opened at $333.81 on Tuesday. C.R. Bard, Inc. has a fifty-two week low of $218.72 and a fifty-two week high of $337.73. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $24,382.50, a PE ratio of 28.89, a PEG ratio of 2.56 and a beta of 0.52.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.06. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The firm had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. During the same period in the prior year, the business earned $2.64 EPS. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. research analysts anticipate that C.R. Bard, Inc. will post 11.89 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be issued a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date is Thursday, December 7th. C.R. Bard’s payout ratio is currently 13.70%.

WARNING: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/c-r-bard-inc-bcr-shares-bought-by-cubist-systematic-strategies-llc/1772757.html.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.